Literature DB >> 16780802

The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity.

Juliane Fritzsche1, Susanne Alban, Ralf J Ludwig, Simone Rubant, Wolf-Henning Boehncke, Gabriele Schumacher, Gerd Bendas.   

Abstract

Selectin-mediated leukocyte rolling along the endothelium is of key importance for maintaining the cellular immune response. The anti-inflammatory activities of heparin have partly been related to inhibition of P-selectin binding. Heparin, however, suffers from its heterogeneous variable structure, the animal origin and multiple in vivo effects. As P-selectin is a promising target for anti-inflammatory approaches, we focused on P-selectin inhibition by other sulfated polysaccharides and compared them with six heparins. We examined 15 structurally defined semisynthetic sulfated glucans, non-animal-derived from the linear glucans phycarin, curdlan or pullulan. The derivatives gradually differ in their degree of sulfation, molecular weight, and glycosidic linkage. The inhibitory capacity was analysed in a parallel plate flow chamber, detecting the rolling of U937 cells on P-selectin layers. Unfractionated heparins displayed variabilities between different preparations. Considering fractionated heparins, exceeding of a minimal mass is essential for activity. Comparing the glucan sulfates, charge density is the most important parameter for P-selectin binding. Highly sulfated derivatives are excellent inhibitors, the reduced cell binding up to 16.2+/-6.4% strongly exceeded the heparin activities. Molecular weight is of minor effects, while glycosidic backbone linkage holds certain importance. To check the P-selectin inhibition in vivo, heparin and one phycarin sulfate were tested using intravital microscopy of microvasculature in mice. Both compounds significantly reduced the rolling fractions of activated platelets on endothelium as effective as a blocking P-selectin antibody. Our study indicates that semisynthetic glucan sulfates with optimal structures block P-selectin excellently and might become promising candidates for anti-inflammatory drugs to replace heparin for certain applications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16780802     DOI: 10.1016/j.bcp.2006.05.006

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  Dendritic polyglycerol sulfates as multivalent inhibitors of inflammation.

Authors:  Jens Dernedde; Alexandra Rausch; Marie Weinhart; Sven Enders; Rudolf Tauber; Kai Licha; Michael Schirner; Ulrich Zügel; Arne von Bonin; Rainer Haag
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

2.  Sulfation modulates the targeting properties of hyaluronic acid to P-selectin and CD44.

Authors:  Deep S Bhattacharya; Denis Svechkarev; Aishwarya Bapat; Prathamesh Patil; Michael A Hollingsworth; Aaron M Mohs
Journal:  ACS Biomater Sci Eng       Date:  2020-05-04

3.  Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita.

Authors:  Ralf J Ludwig
Journal:  ISRN Dermatol       Date:  2013-07-15

Review 4.  The rationale for using low-molecular weight heparin in the therapy of symptomatic COVID-19 patients.

Authors:  Edyta Reichman-Warmusz; Oliwia Warmusz; Romuald Wojnicz
Journal:  Open Med (Wars)       Date:  2022-01-24

5.  Heparin modification improves the re-endothelialization and angiogenesis of decellularized kidney scaffolds through antithrombosis and anti-inflammation in vivo.

Authors:  Jinbo Xie; Jian Wan; Xuemin Tang; Wei Li; Bo Peng
Journal:  Transl Androl Urol       Date:  2021-09

6.  Pharmacological profiles of animal- and nonanimal-derived sulfated polysaccharides--comparison of unfractionated heparin, the semisynthetic glucan sulfate PS3, and the sulfated polysaccharide fraction isolated from Delesseria sanguinea.

Authors:  Inken Groth; Niels Grünewald; Susanne Alban
Journal:  Glycobiology       Date:  2008-12-23       Impact factor: 4.313

7.  Heparin and related drugs: beyond anticoagulant activity.

Authors:  Clive Page
Journal:  ISRN Pharmacol       Date:  2013-07-30

Review 8.  The engagement of selectins and their ligands in colorectal cancer liver metastases.

Authors:  Konstantinos A Paschos; David Canovas; Nigel C Bird
Journal:  J Cell Mol Med       Date:  2010-01       Impact factor: 5.310

Review 9.  Heparin Mimetics: Their Therapeutic Potential.

Authors:  Shifaza Mohamed; Deirdre R Coombe
Journal:  Pharmaceuticals (Basel)       Date:  2017-10-02

10.  Effect of Novel Design Modifications on Fibrotic Encapsulation: An In Vivo Glaucoma Drainage Device Study in a Rabbit Model.

Authors:  Nathan A Fischer; Malik Y Kahook; Suhail Abdullah; Eric Porteous; David A Ammar; Jennifer L Patnaik; Jeffrey R SooHoo
Journal:  Ophthalmol Ther       Date:  2020-03-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.